Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean Frederic Colombel

Showing results (341-350 of 377) with videos related to

Pageof 38
Sort By:
Lancet (London, England)|June 1, 2022
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D'Haens, Remo Panaccione, Filip Baert, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Remo Panaccione, Filip Baert, et al.
Gut|May 4, 2018
Consecutive negative findings on colonoscopy during surveillance predict a low risk of advanced neoplasia in patients with inflammatory bowel disease with long-standing colitis: results of a 15-year multicentre, multinational cohort studyJoren R Ten Hove, Shailja C Shah, Seth R Shaffer, et al.
Lancet (London, England)|October 16, 2012
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trialDavid Laharie, Arnaud Bourreille, Julien Branche, et al.
BMJ Open Gastroenterology|February 9, 2024
Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trialVipul Jairath, Guangyong Zou, Zhongya Wang, et al.
Gastroenterology|May 24, 2024
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)Stephen B Hanauer, Bruce E Sands, Stefan Schreiber, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 30, 2025
The EXTENT Study: Results From an International Expert Delphi Consensus to Define Ultrasonographic Parameters for Measuring Bowel Damage in Crohn's DiseaseCarolina Palmela, Joana Torres, Catarina Frias-Gomes, et al.
Journal of Crohn'S & Colitis|April 17, 2025
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY)Jean-Frederic Colombel, William J Sandborn, Stefan Schreiber, et al.
Inflammatory Bowel Diseases|May 23, 2018
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel DiseaseEugenia Shmidt, Gursimran Kochhar, Justin Hartke, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 10, 2026
Per- and polyfluoroalkyl substances (PFAS) in early life is associated with childhood intestinal inflammation: analyses of three birth cohortsVishal Midya, Amith S Maroli, Mellissa Picker, et al.
Pageof 38

Showing results (341-350 of 377) with videos related to

Sort By:
Pageof 38
Lancet (London, England)|June 1, 2022
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D'Haens, Remo Panaccione, Filip Baert, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Remo Panaccione, Filip Baert, et al.
Gut|May 4, 2018
Consecutive negative findings on colonoscopy during surveillance predict a low risk of advanced neoplasia in patients with inflammatory bowel disease with long-standing colitis: results of a 15-year multicentre, multinational cohort studyJoren R Ten Hove, Shailja C Shah, Seth R Shaffer, et al.
Lancet (London, England)|October 16, 2012
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trialDavid Laharie, Arnaud Bourreille, Julien Branche, et al.
BMJ Open Gastroenterology|February 9, 2024
Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trialVipul Jairath, Guangyong Zou, Zhongya Wang, et al.
Gastroenterology|May 24, 2024
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)Stephen B Hanauer, Bruce E Sands, Stefan Schreiber, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 30, 2025
The EXTENT Study: Results From an International Expert Delphi Consensus to Define Ultrasonographic Parameters for Measuring Bowel Damage in Crohn's DiseaseCarolina Palmela, Joana Torres, Catarina Frias-Gomes, et al.
Journal of Crohn'S & Colitis|April 17, 2025
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY)Jean-Frederic Colombel, William J Sandborn, Stefan Schreiber, et al.
Inflammatory Bowel Diseases|May 23, 2018
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel DiseaseEugenia Shmidt, Gursimran Kochhar, Justin Hartke, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 10, 2026
Per- and polyfluoroalkyl substances (PFAS) in early life is associated with childhood intestinal inflammation: analyses of three birth cohortsVishal Midya, Amith S Maroli, Mellissa Picker, et al.
Pageof 38